Tyenne (tocilizumab-aazg subcutaneous injection – Fresenius Kabi) — Cigna

Initial criteria

• Patient is age > 18 years
• Patient has tried one conventional synthetic DMARD for at least 3 months
• Note: Examples of conventional DMARDs include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine
• An exception to the requirement for a trial of one conventional synthetic DMARD can be made if the patient has already had a 3-month trial with at least one biologic other than a tocilizumab product
• The medication is prescribed by or in consultation with a rheumatologist

Reauthorization criteria

• Patient has been established on therapy for at least 6 months
• Patient experienced a beneficial clinical response when assessed by at least one objective measure OR patient experienced an improvement in at least one symptom

Approval duration

initial 6 months, reauth 1 year